Literature DB >> 23318502

The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs.

L Simonsen1, J J Holst, K Madsen, C F Deacon.   

Abstract

The most striking sequence difference between glucagon-like peptide-1 (GLP-1)(2) and the longer-acting GLP-1 receptor agonist, exendin-4 (Ex-4),(3) is the nine-amino acid COOH-terminal extension of Ex-4. We investigated the contribution of this extension to the survival time of Ex-4. We assessed the overall metabolism of GLP-1, Ex-4, a COOH-terminally extended GLP-1 peptide (GLP-1+Ex(31-39); GLP-Ex),(4) and a COOH-terminally truncated exendin peptide (Ex(1-30)) in anaesthetized, catheterized pigs, with focus on the extraction across the kidneys and a peripheral tissue (a hindleg, representing muscle, adipose- and connective tissue). Peptide analysis was carried out with assays against the mid-region of the peptides, whereby the role of dipeptidyl peptidase-4 (DPP-4)(5) mediated NH(2)-terminal degradation could be disregarded. The half-life of GLP-1 was significantly increased when the COOH-terminal extension of Ex-4 was added (GLP-1 4.8±3.3min; GLP-Ex 19.5±3.3min). In contrast, there was no effect of truncating Ex-4 (Ex-4 32.4±4.1min; Ex(1-30) 28.4±1.7min). Ex-4 and Ex(1-30) were cleared solely by the kidneys at rates corresponding to the glomerular filtration rate (GFR),(6) while GLP-1 and GLP-Ex were cleared by both the kidneys and peripheral tissues. Both extraction rates were, however, significantly reduced with GLP-Ex compared to GLP-1. The renal clearance rate of GLP-1 greatly exceeded GFR, while GLP-Ex was cleared at a rate resembling GFR. In conclusion, the COOH-terminal extension of Ex-4 contributes minimally to the increased survival time of Ex-4, while addition of this sequence to GLP-1 significantly reduces its clearance.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23318502     DOI: 10.1016/j.regpep.2012.12.012

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  5 in total

1.  Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice.

Authors:  Varun Pathak; Srividya Vasu; Victor A Gault; Peter R Flatt; Nigel Irwin
Journal:  Diabetologia       Date:  2015-06-06       Impact factor: 10.122

Review 2.  Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP.

Authors:  Lijing Wang
Journal:  Drug Des Devel Ther       Date:  2022-05-25       Impact factor: 4.319

3.  A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation.

Authors:  Aisling M Lynch; Nupur Pathak; Varun Pathak; Finbarr P M O'Harte; Peter R Flatt; Nigel Irwin; Victor A Gault
Journal:  Diabetologia       Date:  2014-06-25       Impact factor: 10.122

4.  DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.

Authors:  W Wang; X Wen; W Duan; X Wang; Y Chen; J Dong; Z Yang; J Fang; Z Zhou; G Yao; Y Fang; Y Huang
Journal:  J Endocrinol Invest       Date:  2019-11-30       Impact factor: 4.256

5.  A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats.

Authors:  Kirsten M Hoelmkjaer; Nicolai J Wewer Albrechtsen; Jens J Holst; Anna M Cronin; Dorte H Nielsen; Thomas Mandrup-Poulsen; Charlotte R Bjornvad
Journal:  PLoS One       Date:  2016-05-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.